Preventing COVID-19-induced pneumonia with anticytokine therapy

The Lancet Rheumatology

Volumn 2, Issue 5, 2020, Pages e255-e256

  Monteleone, Giovanni ^a   Sarzi Puttini, Pier Carlo ^b   Ardizzone, Sandro ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 6 INHIBITOR; TOCILIZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; AGING; ASYMPTOMATIC INFECTION; COMORBIDITY; CORONAVIRUS DISEASE 2019; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; CYTOKINE STORM; HUMAN; IL 6 SIGNALLING; INCIDENCE; INFECTION PREVENTION; LETTER; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SEPTIC SHOCK; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SIGNAL TRANSDUCTION; VIRUS PNEUMONIA;

EID: 85083834572     PISSN: None     EISSN: 26659913     Source Type: Journal    
DOI: 10.1016/S2665-9913(20)30092-8     Document Type: Letter

References (5)

1. El-Gabalawy, H, Guenther, LC, Bernstein, CN, Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl 85:suppl 85 (2010), 2–10.
2. Dulai, PS, Thompson, KD, Blunt, HB, Dubinsky, MC, Siegel, CA, Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol 12 (2014), 1443–1451.
3. Zhu, N, Zhang, D, Wang, W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382 (2020), 727–733.
4. Chen, C, Zhang, XR, Ju, ZY, He, WF, Advances in the research of cytokine storm mechanism induced by corona virus disease 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi, 36, 2020, e005 [in Chinese].
5. Tanaka, T, Narazaki, M, Kishimoto, T, Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 8 (2016), 959–970.